Spironolactone and canrenoate-K: relative potency at steady state
| Autor: | LE Ramsay, JR Shelton, Ian R Harrison, Michael J Asbury |
|---|---|
| Rok vydání: | 1977 |
| Předmět: |
Agonist
Adult Male medicine.medical_specialty Time Factors medicine.drug_class Metabolite Administration Oral Spironolactone chemistry.chemical_compound Internal medicine Canrenone Pregnadienes medicine Potency Humans Pharmacology (medical) Pharmacology Dose-Response Relationship Drug Chemistry Sodium Solutions Dose–response relationship Endocrinology Therapeutic Equivalency Mineralocorticoid Fludrocortisone Potassium Steady state (chemistry) Canrenoic Acid medicine.drug Tablets |
| Zdroj: | Clinical pharmacology and therapeutics. 21(5) |
| ISSN: | 0009-9236 |
| Popis: | Relative dose ratios of the mineralocorticoid antagonists spironolactone (100 mg and 200 mg daily) and canrenoate-K (200 mg daily) at steady state were defined in six healthy subjects with fludrecortisone as the mineralocorticoid agonist. The urine log 10 Na/K responses during spironolactone treatments were consistent with the law of mass action. The potency of canrenoate-K was 0.68 (95% C.L. 0.53 to 0.89) that of spironolactone on a weight basis. Approximately 72% of the renal antimineralocorticoid activity of spironolactone could attributed to the metabolite canrenone. The results at steady state are contrasted with those of a previously study comparing single doses of spironolactone and canrenoate-K. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|